Trellis presents new data on Influenza and CMV programs at IBC conference in San Diego, Dec 3-6, 2011.
Trellis vice-president and head of R&D Bill Usinger presented an invited lecture in the Tuesday afternoon session of the IBC Antibody Engineering and Therapeutics conference in San Diego, Dec 3-6, 2011. The talk, entitled “Mining Human Blood for Therapeutic Antibodies”, summarized key data from Trellis current preclinical programs in flu and cytomegalovirus (CMV). A poster was also presented that highlighted lead mAb candidates in the flu program.
Influenza. Trellis has completed its exploration of the native human immune repertoire against influenza. High affinity neutralizing antibodies with broad cross-strain reactivity to Group 1 or to Group 2 strains have been isolated and characterized. Excellent efficacy was seen in animals treated post infection.
Cytomegalovirus (CMV). Trellis has identified a high affinity native human antibody to the totally invariant gB (AD-2.1) epitope on CMV. The antibody neutralizes infection by a clinical virus strain (VR1814) of the major cell types relevant to in vivo pathology, including placental cytotrophoblasts. It completely neutralizes all clinical isolates tested to date.